DOK7 gene therapy, agonistic MuSK antibodies and agrin biologicals have proven beneficial in several mouse models for ALS, Dok7 CMS, Emery Dreifuss muscular dystrophy, spinal muscular atrophy or sarcopenia (Arimura et al., 2014; Boido et al., 2018; Cantor et al., 2018; Hettwer et al., 2014; Miyoshi et al., 2017; Sengupta‐Ghosh et al., 2019). The gene discussed is AGRN; the disease is spinal muscular atrophy.